Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alexion to Report Fourth Quarter and Full Year 2019 Results on Thursday, January 30, 2020

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2019 before the US financial markets...

ALXN : 113.27 (+0.68%)
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1

Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.

ALXN : 113.27 (+0.68%)
CLSN : 1.65 (+1.60%)
AVXL : 3.30 (+4.10%)
ASLN : 2.63 (-6.07%)
Momenta (MNTA) Provides Pipeline Updates, Stock Rallies

Shares of Momenta (MNTA) rise 23.7% on pipeline updates.

ALXN : 113.27 (+0.68%)
MNTA : 30.60 (+1.76%)
CLSN : 1.65 (+1.60%)
ASLN : 2.63 (-6.07%)
Alexion Pharmaceuticals (ALXN) Dips More Than Broader Markets: What You Should Know

Alexion Pharmaceuticals (ALXN) closed at $112.79 in the latest trading session, marking a -0.99% move from the prior day.

ALXN : 113.27 (+0.68%)
Ultragenyx Provides Preliminary Crysvita 2019 Revenues

Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.

RARE : 59.96 (-1.51%)
CLSN : 1.65 (+1.60%)
ALXN : 113.27 (+0.68%)
ASLN : 2.63 (-6.07%)
Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS(R) (ravulizumab) in ALS

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the planned initiation of a pivotal Phase 3 study of ULTOMIRIS(R) (ravulizumab) in amyotrophic lateral sclerosis (ALS). The 50-week global study,...

ALXN : 113.27 (+0.68%)
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari

Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.

NVS : 95.93 (+0.87%)
ALNY : 118.82 (-0.44%)
ALXN : 113.27 (+0.68%)
CUE : 15.40 (-8.17%)
Ultragenyx's Gene Therapy Positive in Genetic Disorder Study

Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.

BAYRY : 20.9350 (-0.21%)
ALXN : 113.27 (+0.68%)
RARE : 59.96 (-1.51%)
CUE : 15.40 (-8.17%)
Top Ranked Growth Stocks to Buy for January 13th

Top Ranked Growth Stocks to Buy for January 13th

UI : 170.58 (-0.12%)
LM : 37.75 (-1.41%)
BLD : 111.60 (+1.08%)
ALXN : 113.27 (+0.68%)
Aptevo Therapeutics' Apvo436 Selected For Inclusion In The Leukemia & Lymphoma Society's Groundbreaking Beat Aml(R) Master Clinical Trial

APVO436 is the Latest Investigational AML Therapeutic to be Selected for Participation in the Study; Aptevo Joins Industry Leaders, Bristol-Myers Squib (formerly Celgene) Alexion Pharmaceuticals, Gilead...

AGIO : 52.86 (+2.54%)
ALXN : 113.27 (+0.68%)
ALPMF : 17.4200 (+0.87%)
CELGZ : 0.47 (+2.15%)
GILD : 62.98 (-0.35%)
APVO : 0.68 (-2.16%)
Gilead (GILD) Inks License Deal with Xencor for HIV Candidate

Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.

GSK : 47.89 (+1.55%)
GILD : 62.98 (-0.35%)
ALXN : 113.27 (+0.68%)
XNCR : 37.55 (-0.64%)
Watch for Alexion Pharm to Potentially Pullback After Gaining 1.56% Yesterday

Alexion Pharm (NASDAQ:ALXN) traded in a range yesterday that spanned from a low of $108.89 to a high of $109.22. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of...

ALXN : 113.27 (+0.68%)
Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?

Is (ALXN) Outperforming Other Medical Stocks This Year?

ALXN : 113.27 (+0.68%)
The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals

The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals

BERY : 48.75 (+2.29%)
PPC : 29.50 (-1.42%)
EBS : 55.56 (-0.86%)
ALXN : 113.27 (+0.68%)
HRB : 24.47 (-2.00%)
Relatively Good Performance Detected in Shares of Vertex Pharm in the Biotechnology Industry (VRTX , REGN , ALXN , ABBV , BIIB )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ALXN : 113.27 (+0.68%)
REGN : 385.94 (+0.10%)
VRTX : 235.83 (+0.14%)
Incyte's Application for Pemigatinib Gets EMA's Validation

The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy....

AGIO : 52.86 (+2.54%)
EBS : 55.56 (-0.86%)
INCY : 80.50 (-0.15%)
ALXN : 113.27 (+0.68%)
Amarin Posts '19 Preliminary Results, Gives 2020 Expense View

Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock...

CHRS : 19.16 (-3.55%)
AVXL : 3.30 (+4.10%)
AMRN : 19.91 (-0.75%)
ALXN : 113.27 (+0.68%)
5 Top Value Picks to Counter Recent Stock Market Softness

The stable economic fundamentals of the United States have raised the possibility of the recent stock market volatility being a transitory phase and markets continuing their long-term uptrend.

BERY : 48.75 (+2.29%)
PPC : 29.50 (-1.42%)
EBS : 55.56 (-0.86%)
ALXN : 113.27 (+0.68%)
HRB : 24.47 (-2.00%)
Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study

Apellis Pharmaceuticals' (APLS) experimental drug pegcetacoplan outperformed Alexion's blockbuster medicine, Soliris, in a phase III head-to-head study. Shares soar.

ACHN : 6.19 (-0.80%)
AMGN : 241.49 (+0.41%)
ALXN : 113.27 (+0.68%)
APLS : 40.50 (+0.30%)
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020

Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.

MRK : 90.97 (-0.23%)
SNY : 51.24 (+0.10%)
PFE : 40.51 (-0.25%)
AZN : 51.33 (+1.62%)
JNJ : 149.17 (+0.65%)
LLY : 139.58 (-1.31%)
ALXN : 113.27 (+0.68%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -0.35 , SEDG +2.05 , THC unch , TER -0.21 , LITE -0.79
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar